Head to Head Review: Proteon Therapeutics (PRTO) & Intec Pharma (NTEC)

Proteon Therapeutics (NASDAQ: PRTO) and Intec Pharma (NASDAQ:NTEC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.


This table compares Proteon Therapeutics and Intec Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A -72.02% -64.41%
Intec Pharma N/A N/A N/A

Risk and Volatility

Proteon Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Intec Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Proteon Therapeutics and Intec Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 7 1 0 2.13
Intec Pharma 0 0 4 0 3.00

Proteon Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 250.00%. Intec Pharma has a consensus target price of $12.25, suggesting a potential upside of 53.13%. Given Proteon Therapeutics’ higher probable upside, analysts plainly believe Proteon Therapeutics is more favorable than Intec Pharma.

Institutional & Insider Ownership

47.1% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Intec Pharma shares are owned by institutional investors. 36.3% of Proteon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Proteon Therapeutics and Intec Pharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics $2.95 million 11.95 -$28.52 million ($1.57) -1.27
Intec Pharma N/A N/A -$13.36 million N/A N/A

Intec Pharma has higher revenue, but lower earnings than Proteon Therapeutics.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

What are top analysts saying about Proteon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteon Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit